Cas:5339-69-5 N-propan-2-ylbenzenesulfonamide manufacturer & supplier

Chemical Name:N-propan-2-ylbenzenesulfonamide

CAS.NO:5339-69-5

Synonyms:n-isopropylbenzenesulfonamide;N-isopropylbenzene sulfamide;N-isopropyl-benzensulfonamide;N-Isopropyl-benzolsulfonamid

Molecular Formula:C₉H₁₃NO₂S

Molecular Weight:199.27000

HS Code:2935009090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:305.2ºC at 760mmHg

Density:1.149g/cm3

Index of Refraction:1.524

PSA:54.55000

Exact Mass:199.06700

LogP:2.84500

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like n-isopropylbenzenesulfonamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-Isopropyl-benzolsulfonamid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,n-isopropylbenzenesulfonamide Use and application,N-isopropyl-benzensulfonamide technical grade,usp/ep/jp grade.

Related News: Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress. N-propan-2-ylbenzenesulfonamide manufacturer Biogen has said that some 1.5 million Americans with early-stage Alzheimer’s will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost. N-propan-2-ylbenzenesulfonamide supplier Ultimately there’s likely a broad mix of social, cultural and economic drivers at play, suggested Lona Sandon, program director of the Department of Clinical Nutrition in the School of Health Professions at the UT Southwestern Medical Center in Dallas. She was not part of the research. N-propan-2-ylbenzenesulfonamide vendor Biogen has said that some 1.5 million Americans with early-stage Alzheimer’s will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost. N-propan-2-ylbenzenesulfonamide factory Biogen has said that some 1.5 million Americans with early-stage Alzheimer’s will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost.